Alnylam Pharmaceuticals

This early-stage study tested a single injection of an experimental drug (ALN-TTRSC04) in 96 healthy adults to see if it is safe and how the body processes it. The drug aims to lower a harmful protein that causes transthyretin-mediated amyloidosis, a rare disease affecting the he…

This study tested a new drug called zilebesiran in 663 adults whose high blood pressure was not well controlled by their current medicines. Participants took zilebesiran or a placebo alongside their usual blood pressure pills. The main goal was to see if zilebesiran could lower b…

This study tested a new drug called zilebesiran in 375 adults with high cardiovascular risk and high blood pressure that standard medications couldn't control. Participants took zilebesiran or a placebo alongside their usual blood pressure pills. The goal was to see if zilebesira…

This study tested a new medicine called vutrisiran in 164 adults with a rare, inherited nerve disease (hATTR amyloidosis). Participants received either vutrisiran as a shot every 3 months or another drug every 3 weeks. The goal was to see if vutrisiran could slow nerve damage and…

This study tested an experimental drug called ALN-AGT01 in 394 adults with mild-to-moderate high blood pressure. The goal was to see if it could safely lower blood pressure readings over 24 hours and in the doctor's office. Participants received either the drug or a placebo, and …

This study tested a medicine called patisiran in 360 people with a rare disease where abnormal protein builds up in the heart, causing heart failure. The goal was to see if patisiran could improve how far patients can walk in 6 minutes and their heart-related quality of life afte…

This study tested an experimental drug called zilebesiran in 36 Japanese adults with mild to moderate high blood pressure. The goal was to check its safety and how well it lowers blood pressure compared to a placebo. Participants received either the drug or a dummy shot, and thei…

This early-stage study tested the safety and how the body processes a new drug called ALN-AGT01 RVR. It involved 42 healthy adults who received either a single dose of the drug or a placebo. The main goal was to check for side effects and measure drug levels in the blood and urin…